Previous bioinformatics analysis identified that high H2BC12 predicted adverse outcomes of breast, pancreatic, and ovarian cancers (Li et al., 2018; Li and Zhan, 2019; Yu et al., 2020). This evidence concerns the gene H2BC12 and ovarian carcinoma.